Esperion Therapeutics (ESPR) Equity Ratio (2018 - 2025)
Historic Equity Ratio for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to 1.24.
- Esperion Therapeutics' Equity Ratio fell 520.57% to 1.24 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.24, marking a year-over-year decrease of 520.57%. This contributed to the annual value of 1.13 for FY2024, which is 4886.27% up from last year.
- Per Esperion Therapeutics' latest filing, its Equity Ratio stood at 1.24 for Q3 2025, which was down 520.57% from 1.25 recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Equity Ratio registered a high of 0.52 during Q4 2021, and its lowest value of 2.21 during Q4 2023.
- For the 5-year period, Esperion Therapeutics' Equity Ratio averaged around 1.21, with its median value being 1.18 (2024).
- As far as peak fluctuations go, Esperion Therapeutics' Equity Ratio plummeted by 461013.19% in 2021, and later skyrocketed by 4886.27% in 2024.
- Esperion Therapeutics' Equity Ratio (Quarter) stood at 0.52 in 2021, then plummeted by 153.02% to 1.31 in 2022, then crashed by 69.3% to 2.21 in 2023, then surged by 48.86% to 1.13 in 2024, then fell by 9.67% to 1.24 in 2025.
- Its Equity Ratio stands at 1.24 for Q3 2025, versus 1.25 for Q2 2025 and 1.32 for Q1 2025.